Boltz Raises $110M Series A for Drug Research Software
Boltz has made a promise to its drug-industry customers that is unusually clear for an AI startup: the founders say the company will sell research software rather than develop its own medicines. For a pharmaceutical team handing work to an outside vendor, that choice goes to the heart of the agreement. The laboratory has a reason to ask who benefits if its research works.
Boltz announced a $110M Series A on November 18, 2026, led by Bessemer Venture Partners. The public-benefit corporation says it plans to invest in compute, data and team growth, including the work of meeting demand from pharmaceutical partners. Founders Gabriele Corso, Jeremy Wohlwend and Saro Passaro began the underlying work at MIT. Boltz disclosed its earlier $28M seed round and initial commercial launch in January.
The financing backs an enterprise software model in a sector where a laboratory makes purchasing decisions in the shadow of its own research timelines and obligations. Boltz can supply software on a usage basis, as returning investor Andreessen Horowitz describes. It still has to make sense for someone inside each customer organization to keep buying it when a pilot turns into an expense that can be compared with everything else the team needs.
Bessemer leads a round that pairs software and healthcare investors
Boltz named Bessemer's Andrew Hedin and Byron Deeter in the financing announcement. The firm cites work across life sciences and software. Boltz also lists Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures among returning investors, and Greycroft, F-Prime Capital, Hummingbird and Benchling among new participants. The announcement does not establish the investors' check sizes, valuation, governance rights or ownership.
Benchling's participation is interesting because it comes from a company already in the business of selling software to researchers. It tells us where another operator saw a reason to invest. A check does not establish that two products will be combined, and Boltz did not announce a distribution or integration agreement with Benchling as part of these financing terms. Those would be separate commercial decisions with commitments of their own.
Boltz reports signed relationships with six of the world's 20 largest pharmaceutical companies. Its commercial announcements include Pfizer, GSK and Takeda, alongside other partnerships. Those are customer and collaborator relationships, not a list of buyers of shares in the Series A. They matter because a company selling software into pharmaceutical research has to make its case inside the operating processes of institutions with years of accumulated systems and policies.
Paying activity offers a signal before revenue quality is clear
Boltz reports 50-fold growth since June in usage by paying customers, measured by the volume of tokens it processed. The funding release gives a June baseline for comparison without disclosing the absolute volume or customer-by-customer concentration. The company offered no equivalent revenue-growth figure or independent research outcomes with the round. Growing paid usage can point to a stronger place inside a customer's work without establishing how much of that growth will persist.
Volume also creates expenses. Someone has to provide the computing capacity, support users and make the economics work as additional research groups begin to adopt the product. The investment in compute and staffing follows that demand. It does not tell a reader how much the company earns on the incremental work or how much customer support is required when a tool becomes part of more than one program. Boltz says it has grown to 40 people from the original MIT group. The next hires will be joining a business with large customers to serve alongside the research work that first made those relationships possible.
Another young company in the market, Tesorai, has raised capital around making existing life-science research data usable. Its offer focuses on a different point in the research process. The comparison helps clarify what is being sold: several companies can earn a place in a research organization's budget without owning the product that might ultimately result from the research.
Boltz has chosen to serve organizations that will keep their own clocks
In setting out its commercial mission, Boltz distinguishes building software from building a pipeline of drugs. Customers can engage the company to supply a tool while retaining control of their own research decisions. That arrangement is easier to explain than to sustain. A customer will need to understand what it can retain, what another vendor might replace and how work can continue the next time the system around it changes.
Corso, Wohlwend and Passaro are getting more room to build that service, including the support a larger group of paying customers will expect. The organizations using it will still bring their own scientific and procurement requirements. At the renewal table, the people who worked with the software will be able to say something the announcement cannot: where it earned a place beside the tools their teams would miss if they disappeared.
Frequently Asked Questions
What is Boltz selling to pharmaceutical research teams?
Boltz provides AI research software on a usage basis. It describes its business as selling software rather than building its own portfolio of medicines.
How does the $110M Series A relate to Boltz’s earlier financing?
The $110M round announced in November 2026 is a new Series A led by Bessemer Venture Partners. Boltz announced a separate $28M seed financing in January 2026.
Does Boltz’s 50-fold usage growth measure revenue growth?
No. The company reported 50-fold growth in tokens processed for paying customers since June. It did not disclose equivalent growth in revenue, customer counts or research outcomes.
Are Boltz’s pharmaceutical partners investors in the Series A?
The disclosed commercial relationships and the Series A investor list are distinct. Pfizer, GSK and Takeda appear in commercial announcements rather than as named round investors.
What will the Series A support?
Boltz says the financing will support compute, data, hires and growing demand from its commercial partners. Specific allocation percentages were not disclosed.
Where the Money Moved
The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.
Subscribe to Where the Money Moved



